BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • UK Approves Oxford-AstraZeneca...
      Coronavirus

      UK Approves Oxford-AstraZeneca COVID-19 Vaccine, Roll Out From Jan 4

      Oxford-AstraZeneca vaccine uses an adenoviral vector which carries the SARS-CoV-2 spike protein to elicit an immune response

      By - Shachi Sutaria |
      Published -  30 Dec 2020 2:53 PM IST
    • Boomlive
      UK Approves Oxford-AstraZeneca COVID-19 Vaccine, Roll Out From Jan 4

      The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) approved a two full-dose regime of the Oxford-AstraZeneca AZD1222 COVID-19 vaccine which will be rolled out by January 4 in the country to tackle the ongoing coronavirus pandemic.

      The approval of this frontrunner vaccine by the MHRA comes at a time when a new, more infectious variant of the coronavirus is seen to have emerged from the country. Several countries across the world including India have suspended air travel with the UK to control the spread of this B.1.1.7 variant.

      Oxford University's Jenner institute developed this adenoviral vaccine taken from chimpanzees which is going to be mass produced by Swedish pharmaceutical giant AstraZeneca. The vaccine was shrouded in controversies after its Phase 3 interim results showed that in UK two different doses were administered to participants. While the vaccines two full-doses regime showed 62% efficacy, its one half and one full-dose regime showed 90% efficacy. The UK authorities have however, approved only the two-full doses regime which is likely to begin distribution from January 4.

      Also Read:Oxford-AstraZeneca Says COVID-19 Vaccine Shows 62-90% Efficacy

      The chimpanzee adenovirus acts as a vector to transfer the DNA of the coronavirus spike protein to the human body. Once injected it then facilitates the creation of the spike protein which is identified as a pathogen by the human body. The human body then starts creating antibodies to fight against this induced pathogen.

      Also Read:
      COVID-19 Vaccines For India: All You Need To Know

      Unpublished data accessed by BBC reveals that the efficacy of the two full-doses regime increases if the time period between the first and the second dose is prolonged. Currently, the second dose is administered 28 days after the first one.

      Despite its actual effectiveness still being questioned, the approval of this vaccine will bring cheer to several low- and middle-income countries including India. The AZD1222 vaccine can be stabilised at temperatures used by routine cold chain, uses technology that has been employed for vaccines earlier, and is priced moderately giving it an advantage over both the Moderna and Pfizer mRNA vaccines that require cold chains at very low temperatures and are expensive.

      As part of the World Health Organisation's COVAX- ACT Accelerator, the vaccine will also be equitably distributed across all countries.

      This approval also raises hopes for India. The Indian drug regulator refused to give Serum Institute of India, who is producing the vaccine in India, emergency use authorization as it felt that the data provided by the vaccine maker was insufficient. It also requested the company to provide details from the UK. As the vaccine has now been approved in the UK, the decision of the Indian Subject Expert Committee is now awaited.

      Also Read:Drug Regulator Asks Serum, Bharat Biotech To Provide More Data For EUA


      Tags

      Oxford AstraZeneca VaccineUnited KingdomCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!